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Abstract
Background: Interferon-beta (IFN-β) shows beneficial effect on the course of multiple sclerosis
(MS), nevertheless its route and frequency of administration and side effects might impact
negatively the quality of life (QoL) of MS patients. The objective of this study was to evaluate the
influence of IFN-β on QoL in MS patients.
Methods:  Seventy-seven disease modifying treatment (DMT) free and 41 IFN-β treated MS
patients were evaluated. QoL, assessed by MSQoL-54, was related to IFN-β treatment and to
clinical and demographic parameters at baseline and after two years. Multivariate hierarchical linear
model for repeated measurements was used.
Results: Treated patients showed a younger age, a lower disease duration and a higher relapse
rate in the two years preceding study entry. At inclusion time treated and untreated patients did
not differ in relapse rate, expanded disability status scale (EDSS), fatigue, depression, physical and
mental QoL. IFN-β did not influence QoL at inclusion time, but when QoL was evaluated after two
years, treatment negatively affected mental QoL. Depression and fatigue negatively influenced
physical and mental QoL both at baseline and after two years. EDSS correlated with a poor physical
QoL only at baseline.
Conclusion: IFN-β had a negative impact on QoL over the time in MS patients, influencing mainly
mental QoL. The impairment of QoL in MS was strongly associated with increasing fatigue and
depression, whereas clinical disability had a minor unfavourable role.
Published: 12 December 2006
Health and Quality of Life Outcomes 2006, 4:96 doi:10.1186/1477-7525-4-96
Received: 04 August 2006
Accepted: 12 December 2006
This article is available from: http://www.hqlo.com/content/4/1/96
© 2006 Simone et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Health and Quality of Life Outcomes 2006, 4:96 http://www.hqlo.com/content/4/1/96
Page 2 of 7
(page number not for citation purposes)
Background
In the last years increasing interest focused on QoL instru-
ment as a broader measure of the burden of MS. Recent
studies reported that QoL assessment may provide unique
information often underestimated by the EDSS [1-3],
which remains to date the primary clinical outcome meas-
ure for MS related disability [4]. Several factors may influ-
ence the QoL in MS patients. Previous studies showed
varying results on the relationship between neurological
disability and impaired QoL, suggesting only a partial
contribute of disability on QoL. On the contrary fatigue
and depression are highly associated to a poor QoL [5-
11].
Although the QoL instrument is recommended as an out-
come measure of therapeutic choices and treatment effec-
tiveness, its use is still limited in the routine clinical
approaches [12]. Patient's perspectives derived from life-
long treatment, as well as adherence to prolonged thera-
pies and side-related effects are often underestimated.
Some authors reported a beneficial influence of IFN-β
therapy on QoL [13,14]. Nevertheless, adverse effects
related to treatment may negatively impact QoL [14,15].
The objective of this study was to determine the influence
over the time of IFN-β treatment on QoL in MS patients.
Methods
Patients
A non-randomized study was performed on 127 consecu-
tive patients followed at MS centre of the Department of
Neurological and Psychiatric Sciences of the University of
Bari. The patients were enrolled over three months. At
inclusion time, QoL was evaluated in all patients. After
two years further assessment of QoL was proposed to the
same patients: 93 out of 127 completed the MS QoL ques-
tionnaire, whereas 34 patients refused. Seventy-seven of
127 patients were DMT free and not eligible for immuno-
suppressive or immunomodulatory therapies during the
following two years. Forty-one patients were assuming
IFN-β from 3.6 ± 1.9 months at inclusion: 30 patients
IFN-β 1a (14 Avonex® and 16 Rebif ®) and 11 patients IFN-
β 1b. No patient stopped treatment during two years of
follow-up. Finally 9 of 127 patients started to assume IFN-
β at different time during the study. This latter group was
excluded from the analysis, since the relative low number
of patients and the limited use of the drug might be con-
founding factors for statistical evaluation.
All patients had definite MS, according to Mc Donald cri-
teria [16]. Exclusion criteria were current or past history of
psychiatric disorders, clinical relapse or corticosteroids
drugs in the last three months preceding the observation.
No patient needed anti-depressive treatment for the
whole period of the study. The study was conducted with
local ethical committee approval and with patients writ-
ten informed consent.
Measures
In all patients clinical disability was measured by the
EDSS [4]. Quality of life was assessed by MSQoL-54
instrument developed by Vickrey et al [17] and validated
in an Italian population by Solari at al [18]. The scale con-
sists of 54 items that are distributed in 12 multi-item
scales and 2 single item scales. The instrument includes
questions from Short Form 36-Item Health Survey as a
generic core measure [19] and 18 additional items specific
for MS exploring health distress, sexual function, overall
quality of life, cognitive function and energy. Physical and
mental health composite scores are calculated as a
weighted sum of selected domains to generate a simpli-
fied two-dimension solution to MSQoL-54 instrument.
The subscales for the physical health composite summary
are: physical function, health perceptions, energy, role
limitation-physical, bodily pain, social function and
health distress. The subscales for the mental health com-
posite summary are: overall quality of life, emotional well
being, role limitation-emotional, cognitive function and
health distress. The composite scores range from 0 (poor
health) to 100 (optimal health).
Fatigue severity scale (FSS) consists of nine questions,
ranging from 1 (low fatigue) to 7 (high fatigue) with a
suggested cut-off point of 4.5 [20]. Depression status was
assessed using the Beck Depression Inventory (BDI) con-
sisting of 21 items self-report rating inventory [21]. Cog-
nitive functions were evaluated by Mini Mental State
Examination corrected with school-attendance index
(MMSE-c) [22].
MSQoL-54, FSS and BDI were self-administered in the
presence of an assistant if required by the patients.
Statistical analysis
Patients' baseline characteristics in treated and untreated
groups were compared using Pearson χ2 for categorical
variables and t-student test for continuous variables.
Baseline and changes after two years in clinical items and
QoL scores were expressed as mean ± standard deviation
(SD). T-student test was used to assess differences between
treated and untreated groups at baseline and after two
years of follow-up for all continuous measures. Each
MSQoL-54 component (physical and mental composite
score and relative scales) was analysed with a multivariate
hierarchical linear model for repeated measurements
[23]. Hierarchical linear models are particularly suited for
repeated measurements analysis dealing with unbalanced
designs (i.e. presence of drop-outs). These models allowHealth and Quality of Life Outcomes 2006, 4:96 http://www.hqlo.com/content/4/1/96
Page 3 of 7
(page number not for citation purposes)
to simultaneously assess the impact of baseline and time-
varying covariates on QoL baseline scores and their
changes over time, and also to evaluate, via interaction
terms with the time variable, the impact of baseline cov-
ariates over time.
For each QoL component the baseline covariates were: age
at inclusion, gender (male vs. female), disease duration,
disease course (secondary progressive, SP vs. relapsing
remitting, RR), relapse rate in the two years preceding the
study entry, EDSS, BDI, FSS, MMSE-c and IFN-β treatment
(IFN-β treated vs. untreated groups). Changes in time-var-
ying covariates are expressed as difference between two
years follow-up and baseline assessment. The impact of
changes in relapse rate, EDSS, BDI, FSS and MMSE-c on
changes in QoL scores and the effect of treatment group
over the time were also evaluated.
As to baseline variables, β parameters for continuous cov-
ariates represent the difference in QoL score for each unit
increase in the covariate, and βs for categorical covariates
indicate the difference in QoL for each category respect to
the reference one. As to other variables, βs for time-vary-
ing covariates refer to QoL changes for each unit change in
the covariate over the two years of follow-up, and βs for
time and treatment-by-time interaction indicate QoL
changes over the two years of follow-up in treated and
untreated groups. P-values < 0.05 were considered signif-
icant.
Further, drop-out mechanism was analysed to assess the
extent of informative missing data due to patients who
did not complete the questionnaire after two years of fol-
low-up [24]. All the analyses were performed using SAS
Statistical Package Release 9.1 (SAS Institute, Cary, NC).
Results
Table 1 reports baseline demographic and disease related
patient characteristics according to treatment group. A
prevalence of RR course and female gender characterized
each group, without any statistical difference. Untreated
patients showed a significant higher age at inclusion (p =
0.02) and a longer disease duration (p = 0.04) in compar-
ison to treated patients. At baseline MS groups did not dif-
fer in EDSS, BDI, FSS, physical, mental health composite
scores as well as relative scales. Relapse rate in the two
years before study entry was significantly higher in IFN-β
treated patients (p < 0.0001) (Table 2). After two years of
follow-up mental health composite score (p = 0.006) and
emotional well being score (p = 0.014) significantly
decreased in IFN-β treated group (Table 2).
Results of multivariate hierarchical analysis are summa-
rized in Table 3, 4, 5. At baseline a poor physical health
composite score was significantly associated with a higher
age at inclusion (p = 0.043) and higher EDSS, FSS and BDI
scores (p < 0.0003). A lower mental health composite
score was correlated to increased BDI (p < 0.0001) and
FSS score (p = 0.019). Other unfavourable factors were the
male gender (p = 0.005) and RR course (p = 0.037). As
expected, almost all QoL scales related to the physical
composite score showed a negative association with EDSS
and FSS score. All mental QoL scales were mainly related
to impaired BDI (Table 4 and 5). Treatment did not influ-
ence physical and mental composite scores and relative
subscales at baseline (Table 3, 4, 5).
At Follow-up, worsening in physical and mental QoL
health composite scores (Table 3) and in most of their
subscales (Table 4 and 5) were significantly associated to
higher BDI and FSS scores. Changes in EDSS did not influ-
ence all QoL subscales, except for physical function (p =
0.003). When considering the impact of the treatment on
QoL after two years, the untreated patients did not show
statistical changes in physical and mental health compos-
ite score. The IFN-β treated group showed a worsening in
physical composite score and in most of their relative sub-
scales, even if it was not significant. In this group mental
health composite score significantly worsened over two
years (p = 0.01). In addition emotional well being (p =
0.03) and health distress (p = 0.03) showed significant
negative changes.
Thirty-four patients (28.8%) did not complete the QoL
questionnaire at two years follow-up: 27 belonged to
untreated and 7 to treated group. The assessment of
informative drop-outs did not show significant differ-
ences in all the clinical and QoL measures at baseline
between drop-outs and completers (data not shown).
Discussion
To our knowledge, this study is the first to evaluate the
influence of the therapy on QoL by multivariate hierarchi-
cal analysis and the first to demonstrate a poor QoL in
relation to IFN-β treatment.
At inclusion time treated MS patients showed a younger
age, a lower disease duration and a higher relapse rate in
the two years before study entry in comparison to
untreated group. This latter finding could be explained by
the short period of the treatment at study entry, and in
turn it represented the reason of starting the treatment.
However, the used statistical analysis adjusted for all clin-
ical and demographic inter-group differences. Previous
short and long term IFN-β studies indicated a positive
influence of the treatment on physical QoL [14,26,27]
and mental QoL [28]. Moreover MS patients showed a
good performance in mental QoL domains, also inde-
pendently on the treatment (29, 30). In our study short-
term treatment did not influence physical and mentalHealth and Quality of Life Outcomes 2006, 4:96 http://www.hqlo.com/content/4/1/96
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Q o L .  I n  f a c t  n o  d i f f e r e n c e s  i n  Q o L  s c o r e s  w e r e  f o u n d
between untreated and treated patients. After two years we
observed a slight, even if not significant, worsening in
physical QoL in treated patients, and this was in agree-
ment with another report [31]. The main finding of our
analysis was the negative influence of IFN-β treatment on
mental health composite score and in most of its relative
subscales QoL over the time.
In accordance with several authors fatigue and depression
are undoubtedly significant predictors of a poor QoL,
affecting both physical and mental domains, even after
adjusting for all other clinical factors [6,8,10,11,32].
Although fatigue and depression may be considered the
most frequent side effects during IFN therapy, we found
that their impact on QoL was independent on the therapy,
since FSS and BDI scores did not differ in treated and
untreated patients. Furthermore changes in fatigue and
depression over time induced a progressive worsening of
QoL.
Clinical disability at inclusion was related to a poor phys-
ical QoL [1,6-8,11,30], but its negative influence was not
as much as expected [29]. In fact changes in EDSS over the
time did not impact significantly QoL measures. Disease
duration did not affect the QoL, whereas a higher age at
inclusion was significantly related to a poor physical com-
posite score as well as to physical function, role limitation
Table 2: Time-varying covariates. Means ± SD at baseline and change after 2-years follow-up in untreated and treated MS groups
Untreated n. 77 IFN-β treated n.41 p-value*
Time-varying covariates Baseline Change Baseline Change Baseline Change
Relapse rate** 0.2 ± 0.3 0.0 ± 0.4 0.7 ± 0.5 -0.1 ± 0.6 <0.0001 0.37
EDSS 3.1 ± 1.7 0.4 ± 0.8 3.0 ± 1.8 0.4 ± 1.1 0.84 0.93
BDI 9.5 ± 7.7 1.3 ± 10.3 10.8 ± 9.2 2.2 ± 9.8 0.57 0.88
FSS 2.5 ± 1.8 1.1 ± 1.7 2.8 ± 1.9 1.2 ± 1.8 0.53 0.75
MMSE-c 28.5 ± 2.0 -0.6 ± 2.4 28.1 ± 3.7 -0.5 ± 2.5 0.78 0.70
MSQoL-54 Measures
Physical health composite score 65.5 ± 21.4 -5.5 ± 17.2 65.1 ± 22.3 -9.1 ± 18.9 0.91 0.45
Mental health composite score 69.1 ± 19.8 1.2 ± 20.2 71.6 ± 18.2 -12.1 ± 19.1 0.54 0.006
Physical function 67.7 ± 35.8 -2.3 ± 14.7 69.5 ± 35.4 -8.8 ± 19.1 0.80 0.13
Health perceptions 47.5 ± 23.4 -3.0 ± 23.1 48.7 ± 22.7 -6.0 ± 26.9 0.76 0.64
Energy 47.7 ± 22.6 1.1 ± 23.0 47.0 ± 23.0 -1.2 ± 23.0 0.91 0.57
Role limitation-physical 67.6 ± 43.5 -4.6 ± 42.9 65.2 ± 40.7 -14.3 ± 41.8 0.48 0.52
Bodily pain 79.7 ± 25.7 -8.7 ± 30.9 74.0 ± 29.7 -8.1 ± 28.6 0.39 0.41
Sexual function 83.1 ± 26.6 -6.0 ± 35.6 81.5 ± 27.0 -12.0 ± 36.5 0.67 0.62
Social function 74.2 ± 23.3 -5.8 ± 23.4 74.4 ± 21.3 -10.0 ± 21.5 0.87 0.49
Health distress 70.8 ± 23.0 -2.0 ± 31.6 71.9 ± 20.4 -13.3 ± 24.0 0.98 0.06
Overall quality of life 67.5 ± 19.0 -1.0 ± 22.3 64.4 ± 18.8 -8.6 ± 24.3 0.46 0.17
Cognitive function 78.6 ± 20.6 -0.4 ± 23.0 82.4 ± 20.6 -12.2 ± 23.9 0.31 0.06
Emotional well-being 57.1 ± 22.8 5.4 ± 43.2 59.5 ± 16.7 -21.6 ± 42.5 0.65 0.014
Role limitation- emotional 70.6 ± 43.3 0.4 ± 27.2 78.9 ± 36.3 -6.4 ± 21.0 0.37 0.22
Satisfation with sexual function 60.4 ± 26.7 2.0 ± 34.9 54.3 ± 30.6 -3.7 ± 37.0 0.33 0.40
Change in health 47.1 ± 19.9 0.5 ± 21.3 50.6 ± 22.7 4.6 ± 35.5 0.43 0.36
*p-values refer to t-test between treated and untreated groups at baseline and after 2 years follow-up.
**Relapse rate was evaluated in the 2-years preceding study entry (baseline)and after 2 years of follow-up (change)
Table 1: Baseline characteristics in untreated and treated MS groups
Variable Covariate Untreated IFN-β treated p-value
No. of patients 77 41
Age at disease onset (yrs) 30.3 ± 9.7 28.7 ± 10.5 0.42
Age at inclusion (yrs) 42.1 ± 11.2 36.8 ± 11.5 0.02
Gender Male 28 (36.4) 8 (19.5) 0.06
Female 49 (63.6) 33 (80.5)
Disease duration (yrs) 12.0 ± 7.8 8.9 ± 8.1 0.04
Disease course RR 58 (75.3) 34 (82.9) 0.34
SP 19 (24.7) 7 (17.1)
School education (degree-
yrs)
<5 10 (12.9) 6 (14.6) 0.97
6–8 16 (21) 7 (17.1)
9–13 38 (49.2) 19 (46.3)
>13 13 (16.9) 9 (22)
Data are expressed as means ± SD or n (%). P-values refer to T test or Pearson χ2.Health and Quality of Life Outcomes 2006, 4:96 http://www.hqlo.com/content/4/1/96
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physical, bodily pain and cognitive function. Previous
studies reported lower QoL score in SP in comparison to
RR MS (6, 29, 32). In contrast, we found that RR course
negatively influenced QoL. In our MS population the SP
course was much less frequent than RR course and this
might contribute to a bias in the analysis.
Certainly the relative short period of follow-up, in com-
parison to previous longer longitudinal studies, may rep-
resent a possible limitation of the present study. [30].
Further analysis in a larger number of treated patients is
required in order to evaluate the influence of frequency
and route of administration of IFN-βs
Conclusion
In conclusion this study showed that treatment with IFN-
β had a negative impact on QoL over the time in MS
patients, influencing in particular the mental composite
score. On the contrary, short-term treatment did not affect
the QoL. Depression and fatigue were confirmed as main
Table 4: Predictors of Physical health MSQoL-54 scales by IFN-β treatment (Multivariate hierarchical analysis)
Energy Health perceptions Physical function Role limitation physical Bodily pain Social function
Effect β p β p β p β p β p β p
Intercept* 45.11 <.0001 44.67 <.0001 69.40 <.0001 71.72 <.0001 74.23 <.0001 72.54 <.0001
Age at inclusion -0.12 0.36 0.06 0.68 -0.4 0.01 -0.60 0.03 -0.36 0.04 0.06 0.66
Gender (Male vs. Female) -0.51 0.84 2.00 0.52 1.07 0.75 -17.3 0.003 3.74 0.31 -0.32 0.90
Disease duration -0.02 0.92 -0.36 0.08 0.10 0.64 0.19 0.60 -0.38 0.12 -0.30 0.10
Disease course (SP vs. RR) 9.54 0.03 7.35 0.16 -8.44 0.12 8.77 0.34 17.33 0.004 8.65 0.06
Relapse rate 2-yrs before study entry 0.37 0.90 -2.01 0.58 0.70 0.86 1.39 0.83 -0.20 0.96 3.76 0.24
EDSS -2.33 0.06 -3.54 0.02 -8.44 <.0001 -4.69 0.09 -2.82 0.11 -2.65 0.05
BDI -1.16 <.0001 -0.26 0.20 0.25 0.26 -0.92 0.01 0.22 0.36 -0.66 0.0004
FSS -4.80 <.0001 -6.8 <.0001 -8.69 <.0001 -10.0 <.0001 -9.74 <.0001 -6.72 <.0001
MMSE-c -0.19 0.71 -0.43 0.46 0.05 0.94 -1.90 0.10 0.02 0.98 -0.30 0.57
IFN-β treatment (Yes vs No) 1.43 0.65 3.56 0.32 1.20 0.77 5.03 0.50 4.54 0.32 0.23 0.94
Relapse rate change after 2-yrs 4.96 0.17 2.40 0.61 3.76 0.20 -2.71 0.69 2.96 0.54 6.77 0.08
EDSS change after 2-yrs -0.11 0.95 -1.49 0.54 -4.54 0.003 0.59 0.86 0.70 0.77 -2.72 0.16
BDI change after 2-yrs -0.67 0.0005 -0.48 0.05 -0.14 0.37 -1.59 <.0001 -0.82 0.002 -0.67 0.001
FSS change after 2-yrs -5.20 <.0001 -4.89 0.001 -4.65 <.0001 -4.75 0.03 -5.98 0.0001 -4.39 0.0003
MMSE-c change after 2-yrs -1.09 0.15 0.20 0.84 -0.10 0.87 -3.04 0.04 -0.64 0.53 0.18 0.81
Time** 8.67 0.004 3.36 0.37 -4.84 0.05 -1.00 0.86 -1.81 0.65 0.64 0.84
Time × IFN-β treatment (Yes vs No) -0.76 0.86 -1.72 0.74 -6.15 0.07 -2.54 0.77 3.82 0.50 -1.73 0.69
*Intercept value represents the baseline mean score for reference group (Untreated)
**Time value represents the mean score change for reference group (Untreated) after 2 years of follow-up
Table 3: Predictors of MSQoL-54 composite scores by IFN-β treatment (Multivariate hierarchical analysis)
Physical Health Composite Score Mental Health Composite Score
Effect β p β p
Intercept* 65.08 <.0001 69.31 <.0001
Age at inclusion -0.19 0.043 -0.22 0.06
Gender (Male vs. Female) -1.51 0.43 -6.95 0.005
Disease duration -0.1 0.41 -0.04 0.82
Disease course (SP vs. RR) 3.69 0.24 8.39 0.037
Relapse rate 2-yrs before study entry 0.69 0.75 0.62 0.83
EDSS -3.44 0.0003 -0.85 0.47
BDI -0.59 <.0001 -1.44 <.0001
FSS -6.69 <.0001 -2.08 0.019
MMSE-c -0.28 0.44 0.45 0.34
IFN-β treatment (Yes vs No) -0.09 0.97 2.75 0.36
Relapse rate change after 2-yrs 2.15 0.42 0.60 0.84
EDSS change after 2-yrs -1.57 0.26 1.59 0.31
BDI change after 2-yrs -0.60 <.0001 -1.08 <.0001
FSS change after 2-yrs -5.21 <.0001 -2.48 0.01
MMSE-c change after 2-yrs -0.35 0.53 -0.16 0.81
Time** 1.32 0.54 3.33 0.19
Time × IFN-β treatment (Yes vs No) -1.65 0.58 -9.19 0.01
*Intercept value represents the baseline mean score for reference group (Untreated)
**Time value represents the mean score change for reference group (Untreated) after 2 years of follow-upHealth and Quality of Life Outcomes 2006, 4:96 http://www.hqlo.com/content/4/1/96
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predictors of a poor QoL, whereas clinical disability had a
minor unfavourable impact. In planning interventions for
MS, psychological components of patients have to be
always taken into account. Prospective studies in a larger
sample of MS patients are required to enhance the evi-
dence of the drug impact on QoL [33].
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